Clinical Trial

As Insulet unveils pivotal data, a deeper look reveals a strategy to not just improve tech, but to fundamentally change the daily reality of diabetes.

With its world-first gastric cancer drug heading for approval, Innovent Biologics isn't just offering new hope—it's executing a masterclass in strategic leverage.

Perspective Therapeutics is testing a potent alpha-particle therapy for meningioma, the most common brain tumor, offering a new option where surgery fails.

New data on Syndax Pharma's Revuforj shows a 90% survival rate in a high-risk leukemia group, signaling a potential paradigm shift and major market catalyst.

A call for research on vaccine side effects exposes a deeper crisis: the collapse of public trust in science. Can rigorous data heal a polarized nation?

Bluejay Diagnostics secures critical funding to advance its rapid sepsis test, extending its cash runway but raising questions about shareholder dilution.

Quoin Pharmaceuticals files the first-ever drug application for Peeling Skin Syndrome, offering a glimmer of hope for patients with no treatment options.

As one major allergy drug exits, a biotech startup is testing a new path: a microneedle skin stamp. Is this the future of allergy treatment?

Beyond the headlines of EHA 2026, Eli Lilly's latest data and acquisitions reveal a bold strategy to conquer the hematology market. It's a three-pronged assault.

Inipharm's INI-822 study leverages genetic insights for an oral MASH therapy, challenging injectable rivals and offering new hope for high-risk patients.

A new study on couples' supplements shows impressive well-being gains, but a closer look at the methodology reveals a gap between marketing and hard science.

Aethlon Medical's upcoming financial report is more than a balance sheet; it's a test of viability for its revolutionary Hemopurifier blood filter.

Origin Agritech's gene-editing breakthrough allows corn to mature faster without sacrificing yield, a holy grail for breeders and a boon for global food security.

A new manufacturing deal sees Bluejay Diagnostics bet on U.S. resilience. It's a strategic retreat from global risk for a firm facing a long regulatory road.

A breakthrough in cardiac fibrosis treatment reveals more than a new drug; it signals a systemic shift. How AI and human 'organoids' are making animal models obsolete.

A pivotal trial completes enrollment at a record pace while the AMA lays the groundwork for billing. ShiraTronics is rewriting the medtech playbook.

AbbVie secures EU approval for AQUIPTA as an acute migraine therapy, creating a dual-use drug that challenges rivals and reshapes patient care strategy.

As Nanobiotix joins Europe's tech elite, its nanotech cancer therapy gains a powerful spotlight, signaling a new era for physics-based medicine.

Early data shows a first-in-class oral drug helps immunotherapy work again in resistant tumors, offering a glimpse of hope where options are running out.

Early Phase 1 data for APR-1051 reveals anti-tumor activity and manageable safety, offering a new glimmer of hope for patients with advanced solid tumors.